Political heavyweight praises ST innovation
From Iraqi orphan to the X-FACTOR .. Emmanuel Kelly’s story reads like a movie script. Now he’s working with Coldplay’s Chris Martin on a new album.
Our Family Foundation is now the major sponsor for a special project known as The TLC Ambulance,
New research into the potential benefit of immunotherapy of immunotherapy in pancreatic cancer
Exercise can halt, or even reverse the decline of function and energy that commonly occurs as a result of pancreatic cancer and subsequent treatment regimens.
Our CEO is in Africa with Specialists Without Borders
Rare Cancers Australia Chief Executive Richard Vines discusses STA
ST is committed to leaving an enduring legacy.
Our partner PharmaMar offers this insight
STA prides itself on being innovative and entrepreneurial. We set a new pharma industry benchmark in Australia when we decided to stop bonus payments to our in-field representatives based on sales volumes in their territories. We wanted them to focus on their customers, build real relationships and educate, rather than sell. We think it’s worked. Read more.
Australian oncologist Ric de Boer discusses TAILORx and Oncotype DX
The following article by Sarah-Jane Tasker has appeared in The Australian
A new breast cancer drug shown to reduce the risk of cancer recurrence will soon be made available in Australia, New Zealand and throughout South-East Asia.
It was three years ago that our family decided we wanted to give and support causes beyond our local community. After making this decision, we were made aware of the struggles facing the people of Timor-Leste.
1 in 8 women will develop breast cancer
It’s estimated that more than 3000 Australians will be diagnosed with pancreas cancer this year.
Genetic testing of breast tumours can help some women avoid chemotherapy
By Assoc. Prof. Gary Richardson, Director of Oncology Clinics Victoria and Oncology Services and Assoc. Prof. of Medicine, Monash University
By Richard Vines, CEO & Co-Founder Rare Cancers Australia
Most CML patients can now live a normal life span
Christine Daley was one of the first Australian women to receive the ABRAXANE Wellbeing Kit early in 2017, as part of a pilot program.
Specialised Therapeutics is proud to be named as a silver sponsor of the 2017 Dragons Abreast Australia (DAA) Corporate and Community Challenge. This amazing organisation was founded in Australia in 1998, but the idea of breast cancer survivors taking taking part in dragonboating to stay active, improve strength and connect with others facing similar diagnoses was first raised by a Canadian physician and introducer overseas two years earlier. Sue Bowen joined a team after her diagnosis 17 years ago. She says, "It gave me back my life." This is her story.
ST is a longstanding supporter of the GI Cancer Institute, which saves lives by funding important research into gastro-intestinal cancers, including pancreatic cancer. In a few days, medical oncologist Dr Lorraine Chantrill will walk the Larapinta Trail in the Northern Territory to raise new funds. In this short video, she explains her mission and motivation.
Brain Tumor Alliance Australia co-founder Denis Strangman AM has appeared before the Senate Committee into Funding For Research Into Cancers With Low Survival Rates.
Find out how to order Gelclair by clicking on the link above.
Wendy Dunstone was diagnosed with early breast cancer and chose to have her tumour tested using the genomic test, Oncotype DX to guide decisions on her treatment.
Teresa Hammer was 48 years old, recently re-married and “the happiest I had ever been” when she was diagnosed with triple-negative breast cancer almost three years ago.
Specialised Therapeutics’ Quality Assurance Manager David Wilson explains how we transport specialist medicines to patients around the world
Terry Arnold was devastated when he became one of the estimated 1800 Australians every year who are diagnosed with blood cancer. This is his story.
Our delegates will be attending the BIO International Convention, which returns to Boston Massachusetts this June.
Accomplished Australian journalist and broadcaster Julie McCrossin had frequently hosted and entertained medical professionals at major international cancer conferences. Then she was diagnosed with Stage 4 oropharangeal cancer that had spread to her lymph nodes. She endured chemotherapy and radiation therapy which saved her life, but caused debilitating oral mucositis.
Linda Wilson is a mother, wife, grandmother and nurse who was diagnosed with pancreatic cancer
April 24, 2017: 45 year old Keryn Barnett never really knew what she wanted to do with her life in terms of a career. While always employed, she was missing what she thought was her true calling. It was only after being diagnosed with triple-negative breast cancer in late 2014 and her subsequent treatment, that the answer finally dawned. She is now in her second year of a four-year university course, training to become a radiation therapist. She will soon be helping other cancer patients “and this time it will be them getting zapped, not me!”
ST’s Spanish partner PharmaMar employs a team of dedicated professional divers who are seeking new solutions for cancer, hundreds of metres below the sea’s surface.
We are so proud of our intrepid STA foot soldiers, who last week took on the annual Coastrek challenge and walked 30 kilometres in the name of charity.
A haematology career combines cutting edge medicine with a strong focus on people, according to advanced trainee Dr Joel Wight. We profile his "fortuitous" career in the first of a special series ahead of the Private Cancer Physicians of Australia (PCPA) annual conference in Melbourne this weekend, April 29 and 30, 2017. As a company, ST remains committed to advanced trainee education and are proud to be co-sponsoring this prestigious annual meeting.
While Dr Hilda High was always intent on a career in medicine, her professional life took a few tangents before her true calling again beckoned. Following a dietetics degree and experience in computer programming, Hilda began her medical training relatively late in life, at age 32. Now, at 50, she is among Australia’s telehealth pioneers, after establishing a private cancer genetics clinic in NSW four years ago. Last year she consulted with more than 200 families around the country, sometimes face to face and sometimes remotely. She describes cancer genetics as endlessly fascinating and concedes that working in a private practice has enabled unrivalled flexibility, both personally and professionally. Still, finding her niche has not been without its challenges.
There is hope that a new therapy will one day be available for women with endometrial cancer, following the completion of the clinical phase of an important Phase 3 study of Zoptrex (zoptarelin doxorubicin). Proceed to Press Release issued by Aeterna Zentaris, Inc.
Internationally regarded mucositis expert Professor Dorothy Keefe says managing this extremely debilitating condition is completely central to managing cancer patients properly.
November 21, 2016: Dr Lorraine Chantrill discusses Type 2 diabetes and pancreatic cancer. While no link between these two diseases has been established, Dr Chantrill says tumours can affect normal insulin production and a surprise diabetes diagnosis may sometimes be an early cancer warning.
October 20, 2016: Specialised Therapeutics Australia (STA) has a particular interest in pancreatic cancer and is committed to supporting efforts to advance understanding and improve clinical outcomes in this disease. Testimony to this commitment, we recently sponsored well-known television personality and sports broadcaster Tiffany Cherry to participate in the GI Cancer Institute’s ‘Gutsy Challenge’ - a seven day cycling challenge across Cambodia to raise awareness and vital funding for Australian research into GI cancers.
October 10, 2016: Two and a half years ago, Melbourne based high flyer Shelli Whitehurst was diagnosed with Stage 4 breast cancer. The devastating diagnosis inspired her to found a business that’s now helping other cancer patients around the world.
October, 2015: Specialised Therapeutics Australia (STA) is delighted to announce that ICLUSIG™ has received a confirmed listing date of 1 November 2015.
January, 2014: A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1
March, 2016: Our story as featured in The Australian newspaper on 19 March, 2016 by Sarah-Jane Tasker
June, 2013: Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.
November, 2012: Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.
June, 2012: A new therapy to treat a common hospital superbug* infection Clostridium difficile, will soon be available to Australian & New Zealand patients.
May, 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital.
September, 2011: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas - brain tumours which typically have a poor prognosis.
August, 2010: Hundreds of cancer patients around Australia have had free and subsidised access to a world leading cancer drug, under a compassionate program administered by the family-owned bio-pharmaceutical company which markets the treatment in Australia.
May, 2010: World leading advanced breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) will be in focus at a leading international medical conference in Chicago next week.
Rare Cancers Australia - A focus on less common cancers